Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis vascular wound healing in mice

Journal of Cell Biology

Volumn 140, Issue 1, 1998, Pages 233-245

  Carmeliet, Peter ^a   Moons, Lieve ^a   Dewerchin, Mieke ^a   Rosenberg, Steven ^b   Herbert, Jean Marc ^c   Lupu, Florea ^d   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SANOFI   (France)

^d THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMIN; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CELL SURFACE; ELECTRIC INJURY; IMMUNOELECTRON MICROSCOPY; INTIMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER; WOUND HEALING;

ANIMALS; CELLS, CULTURED; CHEMOTAXIS; FEMALE; FEMORAL ARTERY; MALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICROSCOPY, IMMUNOELECTRON; MUSCLE, SMOOTH, VASCULAR; PLASMIN; RECEPTORS, CELL SURFACE; REGENERATION; TUNICA INTIMA; URINARY PLASMINOGEN ACTIVATOR; WOUND HEALING;

EID: 0031893413     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.140.1.233     Document Type: Article

References (66)

1. Anichini, E., G. Fibbi, M. Pucci, R. Caldini, M. Chevanne, and M. Del Rosso. 1994. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp. Cell Res. 213:438-448.
2. Behrendt, N., E. Ronne, and K. Dano. 1995. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol. Chem. Hoppe. Seyler. 376:269-279.
3. Bendeck, M.P., N. Zempo, A.W. Clowes, R.E. Galardy, and M.A. Reidy. 1994. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75:539-545.
4. Blasi, F., M. Conese, L.B. Moller, N. Pedersen, U. Cavallaro, M.V. Cubellis, F. Fazioli, L. Hernandez-Marrero, P. Limongi, P. Munoz-Canoves, et al. 1994. The urokinase receptor: structure, regulation and inhibitormediated internalization. Fibrinolysis. 8:182-188.
5. Bugge, T.H., T.T. Suh, M.J. Flick, C.C. Daughterty, J. Romer, H. Solberg, V. Ellis, K. Dano, and J.L. Degen. 1995. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270:16886-16894.
6. Bugge, T.H., M.J. Flick, M.J. Danton, C.C. Daugherty, J. Romer, K. Dano, P. Carmeliet, D. Collen, and J.L. Degen. 1996. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA. 93: 5899-5904.
7. Carmeliet, P. and D. Collen. 1995. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Evaluation in transgenic animals. Trends Cardiovasc. Med. 5:117-122.
8. Carmeliet, P., and D. Collen. 1996. Gene manipulation and transfer of the plasminogen system and coagulation system in mice. Semin. Thromb. Hemostasis. 22:525-542.
9. Carmeliet, P., L. Moons, J.-M. Herbert, J. Crawley, F. Lupu, R. Lijnen, and D. Collen. 1997. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ. Res. 81:829-839.
10. Carmeliet, P., L. Schoonjans, L. Kieckens, B. Ream, J. Degen, R. Bronson, R. De Vos, J.J. van den Oord, D. Collen, and R.C. Mulligan. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:419-424.
11. Carmeliet, P., L. Moons, R. Lijnen, M. Baes, V. Lemaître, P. Tipping, A. Drew, Y. Eeckhout, S. Shapiro, F. Lupu, and D. Collen. 1997. Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during atherosclerotic aneurysm formation. Nat. Genet. 17:439-444.
12. Carmeliet, P., L. Moons, R. Lijnen, S. Janssens, F. Lupu, D. Collen, and R.D. Gerard. 1997. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation. 96:3180-3191.
13. Carmeliet, P., L. Moons, V. Ploplis, E.F. Plow, and D. Collen. 1997. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99:200-208.
14. Carmeliet, P., L. Moons, J.M. Stassen, J.J. van den Oord, C. Declercq, M. Kockx, and D. Collen. 1997. A model for arterial neointima formation using perivascular electric injury in mice. Am. J. Pathol. 150:761-777.
15. Clowes, A.W., M.A. Reidy, and M.M. Clowes. 1983. Mechanisms of stenosis after arterial injury. Lab. Invest. 49:208-215.
16. Clowes, A.W., M.M. Clowes, Y.P. Au, M.A. Reidy, and D. Belin. 1990. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ. Res. 67:61-67.
17. Collen, D., and H.R. Lijnen. 1991. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 78:3114-3124.
18. Conese, M., and F. Blasi. 1995. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haemotol. 8:365-389.
19. Crowley, C.W., R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, A.D. Levinson. 1993. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:5021-5025.
20. De Petro, G., A. Copeta, and S. Barlati. 1994. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. Exp. Cell Res. 213:286-294.
21. Declerck, P.J., M. Verstreken, F. De Cock, P. Carmeliet, and D. Collen. 1995. Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. J. Biol. Chem. 270:8397-8400.
22. Deng, G., S.A. Curriden, S. Wang, S. Rosenberg, and D.J. Loskutoff. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated adhesion and release? J. Cell Biol. 134: 1563-1571.
23. Dewerchin, M., A.Van Nuffelen, G. Wallays, A. Bouche, L. Moons, P. Carmeliet, R.C. Mulligan, and D. Collen. 1996. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97:870-878.
24. Dollery, C.M., J.R. McEwan, and A.M. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863-868.
25. Ellis, V., M.F. Scully, and V.V. Kakkar. 1989. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264:2185-2188.
26. Estreicher, A., A. Wohlwend, D. Belin, W.D. Schleuning, and J.D. Vassalli. 1989. Characterization of the cellular binding site of the urokinase-type plasminogen activator. J. Biol. Chem. 264:1180-1189.
27. Higazi, A.A., A. Mazar, J. Wang, R. Reilly, J. Henkin, D. Kniss, and D. Cines. 1996. Single-chain urokinase type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 87:3545-3549.
28. Kanse, S.M., C. Kost, O.G. Wilhelm, P.A. Andreasen, and K.T. Preissner. 1996. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224:344-353.
29. Lee, S.W., M.L. Kahn, and D.A. Dichek. 1992. Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. J. Biol. Chem. 267:13020-13027.
30. Libby, P. 1995. Molecular basis of the acute coronary syndromes. Circulation. 91:2844-2850.
31. Libby, P., D. Schwartz, E. Brogi, H. Tanaka, and S.K. Clinton. 1992. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 86(Suppl.):47-52.
32. Lijnen, H.R., B. Van Hoef, and D. Collen. 1996. Characterization of the murine plasminogen/urokinase-type plasminogen activator system. Eur. J. Biochem. 241:840-848.
33. Lupu, F., I. Danricu, and N. Simionescu. 1987. The development of intracellular lipid deposits in the lipid laden cells of the atherosclerotic lesions. A cytochemical and ultrastructural study. Atherosclerosis. 67:127-142.
34. Lupu, F., G.E. Bergonzelli, D.A. Heim, E. Cousin, C.Y. Genton, F. Bachmann, and E.K.O. Kruithof. 1993. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler. Thromb. 13:1090-1100.
35. Lupu, F., D.A. Heim, F. Bachmann, M. Hurni, V.V. Kakkar, and E.K. Kruithof. 1995. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15:1444-1455.
36. Martinez, J., and J.F. Santibanez. 1994. Surface-associated plasminogen activation in leukemic cells: interaction with extracellular matrix. Eur J. Cell Biol. 64:257-263.
37. McGuire, P.G., and N.W. Seeds. 1989. The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. J. Cell. Biochem. 40:215-227.
38. Min, H.Y., L.V. Doyle, C.R. Vitt, C.L. Zandonella, J.R. Stratton-Thomas, M.A. Shuman, and S. Rosenberg. 1996. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res. 56:2428-2433.
39. Moser, T.L., J.J. Enghild, S.V. Pizzo, and M.S. Stack. 1995. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J. 307: 867-873.
40. Murphy, G. 1995. Matrix metalloproteinases and their inhibitors. Acta. Orthop. Scand. Suppl. 66:55-60.
41. Okada, S.S., J.E. Tomaszewski, and E.S, Barnathan. 1995. Migrating vascular smooth muscle cells polarize cell surface urokinase receptor after injury in vitro. Exp. Cell Res. 217:180-187.
42. Ossowski, L. 1996. Effect of antisense inhibition of urokinase receptor on malignancy. Curr. Top. Microbiol. Immunol. 213:101-112.
43. Rabbani, S.A., A.P. Mazar, S.M. Bernier, M. Haq, I. Bolivar, J. Henkin, and D. Goltzman. 1992. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267: 14151-14156.
44. Rao, N.K., G.P. Shi, and H.A. Chapman. 1995. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest.. 96:464-474.
45. Reidy, M.A., C. Irvin, and V. Lindner. 1996. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78:405-414.
46. Resnati, M., M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi, and F. Fazioli. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO (Eur. Mol. Biol. Organ.) J. 15:1572-1582.
47. Sabapathy, K.T., M.S. Pepper, F. Keifer, U. Möhel-Steinlein, F. Tacchini-Cottier, I. Fetka, G. Breier, W. Risau, P. Carmeliet, R. Montesano, and E.F. Wagner. 1997. Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J. Cell Biol. 137:953-963.
48. Salonen, E.M., A. Zitting, and A. Vaheri. 1984. Laminin interacts with plasminogen and its tissue-type activator. FEBS (Fed. Eur. Biochem. Soc.) Lett. 172:29-32.
49. Sato, K., and D. Rifkin. 1988. Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol. 107:1199-1205.
50. Schmitt, M., O. Wilhelm, F. Janicke, V. Magdolen, U. Reuning, H. Ohi, N. Moniwa, H. Kobayashi, U. Weidle, and H. Graeff. 1995. Urokinase-type plasminogen activator (u-PA) and its receptor (CD87): a new target in tumor invasion and metastasis. J. Obstet. Gynaecol. 21:151-165.
51. Silverstein, R.L., P.C. Harpel, and R.L. Nachman. 1986. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. J. Biol. Chem. 261:9959-9965.
52. Silverstein, R.L., R.L. Nachman, R. Pannell, V. Gurewich, and P.C. Harpel. 1990. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. [published erratum appears in J. Biol. Chem. 1990. 265:16025.] J. Biol. Chem. 265:11289-11294.
53. Sitrin, R.G., R.F. Todd, E. Albrecht, and M.R. Gyetko. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest. 97:1942-1951.
54. Stephens, R.W., A.M. Bokman, H.T. Myohanen, T. Reisberg, H. Tapiovaara, N. Pedersen, J. Grondahl Hansen, M. Llinas, and A. Vaheri. 1992. Heparin binding to the urokinase kringle domain. Biochemistry. 31:7572-7579.
55. Stephens, R.W., M. Aumailley, R. Timpl, T. Reisberg. H. Tapiovaara, H. Myohanen, J. Murphy-Ullrich, and A. Vaheri. 1992. Urokinase binding to laminin-nidogen. Structual requirements and interactions with heparin. Eur. J. Biochem. 207:937-942.
56. van Leeuwen, R.T. 1996. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis. 10:59-74.
57. Vassalli, J.D. 1994. The urokinase receptor. Fibrinolysis. 8:172-181.
58. Waltz, D.A., and H.A. Chapman. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269: 14746-14750.
59. Wei, Y., M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosenberg. M.V. Doyle, and H.A. Chapman. 1996. Regulation of intergrin function by the urokinase receptor. Science. 273:1551-1555.
60. Wilhelm, O., U. Weidle, S. Hohl, P. Rettenberger, M. Schmitt, and H. Graeff. 1994. Recombinant soluble urokinase receptor as a scavenger for Urokinase-type plasminogen activator (u-PA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS (Fed. Eur. Biochem. Soc) Lett. 337:131-134.
61. Wong, W.S., D.I. Simon, P.M. Rosoff, N.K. Rao, and H.A. Chapman. 1996. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1 (CD11B/CD18) and urokinase receptor (CD87) Immunology. 88:90-97.
62. Xing, R.H., and S.A. Rabbani. 1996. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer. 67:423-429.
63. Xue, W., A.L. Kindzelskii, R.F.R. Todd, and H.R. Petty. 1994. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 152:4630-4640.
64. Yebra, M., G.C.N. Parry, S. Stromblad, N. Mackman, S. Rosenberg, B.M. Mueller, and D.A. Cheresh. 1996. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ-5-directed cell migration. J. Biol. Chem. 271:29393-29399.
65. Yu, H.R., and R.M. Schultz. 1990. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50:7623-7633.
66. Yu, W., J. Kin, and L. Ossowski. 1997. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 137:767-777.